Shopping Cart
- Remove All
Your shopping cart is currently empty
Z-DEVD-FMK (Caspase-3 Inhibitor) is a Caspase-3 inhibitor (IC50=18 μM), featuring selectivity, irreversibility and cell permeability. Z-DEVD-FMK can inhibit caspase activation induced apoptosis.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $52 | In Stock | |
| 5 mg | $146 | In Stock | |
| 10 mg | $246 | In Stock | |
| 25 mg | $417 | In Stock | |
| 50 mg | $595 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $216 | In Stock |
| Description | Z-DEVD-FMK (Caspase-3 Inhibitor) is a Caspase-3 inhibitor (IC50=18 μM), featuring selectivity, irreversibility and cell permeability. Z-DEVD-FMK can inhibit caspase activation induced apoptosis. |
| Targets&IC50 | Caspase-3:18 μM. |
| In vitro | METHODS: v-K-ras transformed normal rat kidney cells KNRK were treated with SCH56582 (20 µM) and Z-DEVD-FMK (20-50 µM) for 24 h. Cell death was detected using trypan blue.
RESULTS: Addition of 50 µM Z-DEVD-fmk resulted in >70% inhibition of apoptosis. [1] METHODS: Human multiple myeloma cells KM3 were treated with betulinic acid (15 µg/mL) and Z-DEVD-FMK (50 mol/L) for 24 h, and the expression level of target proteins was detected using Western Blot. RESULTS: Z-DEVD-FMK attenuated the betulinic acid-induced activation of caspase 3. Z-DEVD-FMK significantly blocked the cleavage of PARP. Z-DEVD-FMK significantly blocked PARP cleavage. [2] |
| In vivo | METHODS: To test the in vivo activity, Z-DEVD-FMK (1.8 mg/kg in ethanol and freshly diluted in PBS containing 2% Tween-80) was injected intraperitoneally into C57BL/6 mice, followed by CPT-11 (350 mg/kg) 30 min later. Z-DEVD-FMK was continued to be administered once daily for three days.
RESULTS: Caspase-3 inhibitor Z-DEVD-FMK attenuated PT-11-induced GATA6-deficient mouse peritoneal macrophages. [3] |
| Kinase Assay | Caspase activity assay : Caspase-3 and caspase-9 activities are measured using fluorescent-based substrate. After treatment, the cells are resuspended in lysis buffer (50 mM Tris HCl, 1 mM EDTA, and 10 mM EGTA) containing 10 mM digitonin for 20 min at 37°C. Supernatants are treated with either of the fluorogenic substrates Ac-DEVD-AFC for caspase-3 or Ac-LEHD-AFC for caspase-9 for 1 h at 37°C and fluorescence is measured at excitation at 400 nm and emission at 505 nm using a Gemini XS fluorescence plate reade |
| Cell Research | N27 cells are incubated with 100 μM 6-OHDA for 24 h or 300 μM MPP+ for 36 h in the presence or absence of 50 μM Z-DEVD-FMK and cell death is determined by MTT (3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bromide) assay, which is widely used to assess cell viability. After treatment, the cells are incubated in serum-free medium containing 0.25 mg/ml MTT for 3 h at 37°C. Formation of formazan from tetrazolium is measured at 570 nm with a reference wavelength at 630 nm using a SpectraMax microplate reader.(Only for Reference) |
| Synonyms | Caspase-3 Inhibitor |
| Molecular Weight | 668.66 |
| Formula | C30H41FN4O12 |
| Cas No. | 210344-95-9 |
| Smiles | COC(=O)CC[C@H](NC(=O)[C@H](CC(=O)OC)NC(=O)OCc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)OC)C(=O)CF |
| Relative Density. | 1.260 g/cm3 (Predicted) |
| Storage | store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 252.5 mg/mL (377.62 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (7.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.